Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
Anna P. Andreou, Matteo Fuccaro, Bethany Hill, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 19

Showing 19 citing articles:

Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies
Viviana Nociti, Marina Romozzi, Pietro Annovazzi, et al.
Journal of the Neurological Sciences (2025) Vol. 469, pp. 123392-123392
Closed Access | Times Cited: 2
Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications
Britt W. H. van der Arend, Floor C. van Welie, Michael Hecht Olsen, et al.
Cephalalgia (2025) Vol. 45, Iss. 1
Closed Access | Times Cited: 2
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 40
Switching between anti-cgrp monoclonal antibodies in migraine prophylaxis
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access | Times Cited: 1
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
Giorgio Lambru, Valeria Caponnetto, Bethany Hill, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 5, pp. 1284-1293
Open Access | Times Cited: 17
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Refractory migraine
Г. Р. Табеева, O. V. Kosivtsova, N. A. Kovalchuk, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 2, pp. 76-86
Open Access | Times Cited: 5
Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 948-948
Open Access | Times Cited: 5
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3218-3218
Open Access | Times Cited: 10
Unmasking the relationship between CGRP and glutamate: from peripheral excitation to central sensitization in migraine
Fahimeh Martami, Kathleen F. Holton
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Hellenic Headache Society Recommendations for the Use of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide Pathway for the Prevention of Migraine and Cluster Headache—2023 Update
Dimos D. Mitsikostas, A. Alexoudi, Chrysa Arvaniti, et al.
SN Comprehensive Clinical Medicine (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 9
Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis
Jaime Fernández-Bravo-Rodrigo, Iván Cavero‐Redondo, Maribel Lucerón‐Lucas‐Torres, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176702-176702
Closed Access | Times Cited: 3
Cgrp Monoclonal Antibodies: Key Lessons from Real World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
(2024)
Open Access | Times Cited: 2
One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study
Michel Lantéri‐Minet, R. Fabre, Caroline Martin, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Migraine headache pathophysiology
Anna P. Andreou, Ana David-Pereira
Handbook of clinical neurology (2023), pp. 61-69
Closed Access | Times Cited: 6
Calcitonin gene-related peptide inhibitors in the treatment of migraine in the pediatric and adolescent populations: a review
Lisa A. Moore, Ann Pakalnis
Pediatric Neurology (2024) Vol. 157, pp. 87-95
Closed Access | Times Cited: 1
Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review
Délia Szok, Anett Csáti, László Vécsei, et al.
Life (2023) Vol. 13, Iss. 3, pp. 665-665
Open Access | Times Cited: 3
Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies
Vinícius Lins Ferreira, Felipe F. Mainka, Astrid Wiens, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 9, pp. 669-680
Closed Access | Times Cited: 3
Exploring Erenumab’s Efficacy and Safety for Migraine Prevention in Real-World Settings: A Systematic Review
Mah Rukh Nisar, Rudrani Kotha, Sabaa I Saad-Omer, et al.
Cureus (2024)
Open Access
Page 1

Scroll to top